| Literature DB >> 27089966 |
André Toussaint1, Anne Richter2, Frederick Mantel2, John C Flickinger3, Inga Siiner Grills4, Neelam Tyagi4, Arjun Sahgal5, Daniel Letourneau6, Jason P Sheehan7, David J Schlesinger7, Peter Carlos Gerszten3, Matthias Guckenberger2,8.
Abstract
BACKGROUND: The aim of this study was to quantify the variability in spinal radiosurgery (SRS) planning practices between five international institutions, all member of the Elekta Spine Radiosurgery Research Consortium.Entities:
Keywords: Delineation; Planning variability; Spine radiosurgery; Vertebral metastases
Mesh:
Year: 2016 PMID: 27089966 PMCID: PMC4835862 DOI: 10.1186/s13014-016-0631-9
Source DB: PubMed Journal: Radiat Oncol ISSN: 1748-717X Impact factor: 3.481
Detailed patient status parameters
| Patient case: | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
| Sex | F | F | F | M |
| Age | 55 | 61 | 63 | 55 |
| Histology: | Breast | Breast | Lung | Renal |
| Pain Score VAS | 7 | 5 | 6 | - |
| Paraspinal involvement: | Yes | No | Yes | Yes |
| Bilsky score: | 1b | 0 | 0 | 2 |
| Circumferential epidural disease: | 180° | 90° | 90° | 180° |
| Location: | T 12-L1 | C 2 | T 7–8 | L 3 |
| Number of involved vertebras: | 2 | 1 | 2 | 1 |
Fig. 1Representative slices from T2 weighted MR images of all patient cases. Case 1,3,4 are presented in axial view and case 2 in sagittal view
Normal tissue constraints
| Serial tissue | Volume in cm3 | Dose Max in Gy | Endpoint (> Grade 3) |
|---|---|---|---|
| Spinal cord | <0.035 | 14 | Myelitis |
| <0.35 | 10 | ||
| <1.2 | 7 | ||
| Cauda Equina | <0.035 | 16 | Neuritis |
| <5 | 14 | ||
| Sacral Plexus | <0.035 | 18 | Neuropathy |
| <5 | 14.4 | ||
| Esophagusa | <0.035 | 16 | stenosis/fistula |
| <5 | 11.9 | ||
| Heart/Pericardium | <0.035 | 22 | Pericarditis |
| <15 | 16 | ||
| Great vesselsa | <0.035 | 37 | Aneurysm |
| <10 | 31 | ||
| Tracheaa and Larynx | <0.035 | 20.2 | stenosis/fistula |
| <4 | 10.5 | ||
| Skin | <0.035 | 26 | Ulceration |
| <10 | 23 | ||
| Stomach | <0.035 | 16 | ulceration/fistula |
| <10 | 11.2 | ||
| Renal hilum/vascular trunk | <2/3 volume | 10.6 | malignant hypertension |
| Parallel tissue | Critical volume in cm3 | Dose Max | Endpoint (> Grade 3) |
| Lung (Right & Left) | 1000 | 7.4 | Pneumonitis |
| Renal cortex (Right & Left) | 200 | 8.4 | Basic renal function |
a Avoid circumferential irradiation
Fig. 2Schematic illustration of how the delineation variability was determined
Registration variability between the five institutions
| case | X in mm | Y in mm | Z in mm | rot X in ° | rot Y in ° | rot Z in ° | |
|---|---|---|---|---|---|---|---|
| Max range |
| 4.7 | 2.2 | 2.7 | 3.1 | 0.8 | 4.4 |
|
| 1.7 | 1.1 | 6.5 | 1.2 | 3.7 | 3.8 | |
|
| 1.8 | 15.9 | 11.8 | 4.1 | 2.9 | 4.5 | |
|
| 2.6 | 2.5 | 3.0 | 12.5 | 2.6 | 3.5 | |
|
| 2.7 | 5.4 | 6.0 | 5.2 | 2.5 | 4.1 | |
|
|
|
|
|
|
|
| |
| SD |
| 1.7 | 0.9 | 1.0 | 1.1 | 0.4 | 1.6 |
|
| 0.7 | 0.4 | 2.5 | 0.5 | 1.7 | 1.4 | |
|
| 0.7 | 6.9 | 4.8 | 1.7 | 1.2 | 1.8 | |
|
| 1.2 | 1.0 | 1.5 | 4.6 | 1.0 | 1.3 | |
|
| 1.1 | 2.3 | 2.5 | 2.0 | 1.1 | 1.5 | |
|
|
|
|
|
|
|
|
Abbreviations: x (left-right), y (anterior-posterior) and z (superior-inferior) direction; SD; standard deviation; average 1; 2; 4 (bold) excludes outlier case 3
GTV definition variability between the five institutions
| SD in mm | Range in mm | |||
|---|---|---|---|---|
| Case | X and Y | Z | X and Y | Z |
| 1 | 1.3 | 0.6 | 3.1 | 1.5 |
| 2 | 1.7 | 3.4 | 4.1 | 8.1 |
| 3 | 1.3 | 0.9 | 2.5 | 2.0 |
| 4 | 1.8 | 1.5 | 4.0 | 3.6 |
| Average | 1.5 | 1.6 | 3.5 | 3.8 |
CTV definition variability between the five institutions
| SD in mm | Range in mm | |||
|---|---|---|---|---|
| Case | X and Y | Z | X and Y | Z |
| 1 | 0.6 | 0.3 | 1.6 | 0.8 |
| 2 | 1.3 | 3.0 | 3.0 | 6.9 |
| 3 | 0.5 | 0.6 | 1.0 | 1.4 |
| 4 | 0.9 | 1.0 | 1.9 | 2.3 |
| Average | 0.8 | 1.2 | 1.8 | 2.8 |
ICRU report parameters with average values over all cases
| PTV | ||
|---|---|---|
| Dmin in Gy | 7.5 | ±1.8 |
| D98 in Gy | 12.2 | ±2.0 |
| D95 in Gy | 15.2 | ±1.7 |
| D90 in Gy | 17.4 | ±1.0 |
| Dmean in Gy | 19.4 | ±0.8 |
| D05 in Gy | 21.6 | ±1.3 |
| D02 in Gy | 21.9 | ±1.4 |
| Dmax in Gy | 23.1 | ±1.6 |
Mean of doses and volumes to PRV_SC-Consensus
| Dmax in Gy | D0.1ccm in Gy | V8Gy in ccm | V10Gy in ccm | |||||
|---|---|---|---|---|---|---|---|---|
| Dose to PRV_SCconsensus (Mean ± SD) | 10.5 | ±1.6 | 9.0 | ±1.5 | 1.5 | ±1.6 | 0.1 | ±0.1 |
Fig. 3ICRU dose report parameters for one exemplary case (case 1) for all 5 participating institutions. The connecting lines should enhance the distinction between institutions
Fig. 4a/b Maximum planning risk volume spinal cord (PRV_SC) doses to PTV minimum doses and dose to 0,1ccm of spinal cord to PTV D98 for all cases and institutions
Mean performance parameters for all cases
| Case | CI-Paddick | CI-RTOG | HI-RTOG | Cov-RTOG | ||||
|---|---|---|---|---|---|---|---|---|
| 1 | 0.67 | ±0.08 | 1.11 | ±0.17 | 1.98 | ±0.34 | 0.86 | ±0.06 |
| 2 | 0.63 | ±0.08 | 1.19 | ±0.24 | 1.64 | ±0.17 | 0.86 | ±0.05 |
| 3 | 0.70 | ±0.07 | 1.09 | ±0.15 | 1.90 | ±0.31 | 0.87 | ±0.04 |
| 4 | 0.72 | ±0.05 | 1.10 | ±0.12 | 1.90 | ±0.44 | 0.89 | ±0.05 |
| mean | 0.68 | ±0.08 | 1.12 | ±0.18 | 1.86 | ±0.35 | 0.87 | ±0.05 |
Fig. 5Performance parameters RTOG coverage for all analyzed plans. Abbreviation: results of case 1–4 with consensus (c) and individual (i) plans
Fig. 6Performance parameters CI-Paddick for all analyzed plans